barclay global healthcar confer take place march
miami beach fl help investor navig divers issu biopharma
recircul previous publish list question view
topic relev largest compani market cap either present
host meet confer look forward see
pharma diversif priorit upsid lever industri price
dynam beyond given recent discuss administr strategi
mitig zytiga loss wake gener launch outlook line extens
priorit pipelin expans intern vs extern asset near term
tanezumab data expectations/fil timelin strategi rcc javelin given
recent competitor data outlook tafamidi follow approv
outlook i/o evolut space spend strategi product mix outsid
class expans trulic outlook upcom rewind data emerg
celgen acquisit rationale/confid sharehold vote lung strategi
eu humira biosimilar erosion/outlook strategi us humira
look forward orilissa launch trajectory/first mover advantag upadacitinib
hiv landscap evolut biktarvi growth trajectori hiv/reimburs
discuss ou prep strategi outlook yescarta commerci uptak strategi
nash follow failur outlook jak class filgotinib
jakafi growth outlook especi gvhd ahead launch chang olumi
strategi given real-world data/rec xeljanz news pemigatinib posit
bladder cancer priorit early-stag pipelin
expectations/timelin tripl combin file eu
reimburs negoti tripl combo outlook cf beyond tripl pipelin
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
industri dynam strategi could give us sens
upsid opportun lever your look forward year
portfolio mix/bd strategi think diversif js pharma
busi bd approach go forward
 repres slower year term pharma growth give us
sens confid long-term outlook above-market growth js
price dynam outlook on-going price debat
look beyond year especi light recent senat hear
zytiga gener recogn like cant provid concret updat
zytiga eros curv evolv recent month give us sens
near-term strategi look like anyth gener launch surpris
you/warr shift overal strategi
futur growth opportun think line extens drive top-
line growth go forward priorit strategi
eclips data color convers fda file
physician feedback youv receiv term might impact
 maia data file yet expect prioriti review
think market opportun go forward
imbruvica think label expans
imbruvica gazyva expect heredo think imbruvica
gazyva combo could supersed single-ag imbruvica cll/sll
immuno-oncolog what strategi immuno-oncolog go forward
look becom major player i/o space ye see space
evolv time
one-on-on meet
outlook give us sens upsid opportun lever your
look year progress think growth/headwind
innov health essenti health busi segment
 outlook key driver prevnar ibranc eliqui xtandi
portfolio mix/bd strategi pipelin diversif strategi
pharma busi think late-stag pipelin term drive
meaning growth
 repres slower period growth give us sens
confid long-term outlook current pipelin
prioriti expand late-stage/commerci pipelin near term period
slow growth
price dynam outlook on-going price debat
look beyond year especi light recent senat hear
tanezumab expect anti-ngf tanezumab phase eli
lilli especi given challeng develop class assum data
support approv long-term safeti data tanezumab fit
rcc strategi strategi rcc go forward follow javelin renal
data light recent data merck rcc expect
regimen fit treatment landscap
 think presenc i/o space willing
expand oncolog portfolio strategi primarili bavencio combin
tafamidi outlook upcom pdufa tafamidi juli eu file expect
give us updat prepar launch see
tafamidi play role ttr space given activ player space line alnylam
ioni expect label convers
fda/ema affect outlook product candid
provid updat regard remicade-biosimilar inflectra lawsuit
think timelin
one-on-on meet
i/o market develop see registr data emerg across major io
indic keytruda seem separ key competitor
think io posit go forward overal strategi
continu trajectori
adjuvant/neoadjuv new indic tri penetr cold tumor market
earlier
give us sens upsid opportun lever your look
year progress given higher impact readout behind us
lung updat commerci dynam us ou provid us
color reimburs convers evolv eu
rcc strategi thought strength recent
data see keytruda penetr market go forward light
recent file came ahead expect pdufa june see
becom standard care across patient physician feedback
 melanoma thought adjuv market opportun light
recent approv seen immedi uptak follow label extens
 readout year would highlight
investor high-
impact/import growth neo/adjuv tnbc expect
 spend keytruda import driver top-lin growth go forward
keytruda trial current on-going signific amount spend
devot clinic develop give us sens think
oper expens spend next month beyond well
strategi keep pace spend given potenti unlock valu across
combin approach expect slow look past
product mix opportun differenti portfolio outsid
keytruda think growth lynparza gardasil need
diversif asset see room pipelin expans
busi develop given current environ think
busi develop respect current pipelin think sizeabl
bolt-on deal necessari sustain merck long-term growth collabor
outlook/strategi give us sens upsid opportun
lever your look year progress think portfolio
mix diversif asset
capit alloc light recent announc loxo oncolog acquisit
approach a/busi envelop go forward small larger-
loxo rational talk strateg rational behind recent
announc loxo acquisit made attract deal compani
see play role growth profil go forward
class thought on-going class expans
continu outpac insulin think
expans look month
 perceiv risk potenti long-term price compress
categori light emerg competit oral agent
term rewind see opportun expans play
trulic individu also class overal
emgality/cgrp dynam provid us updat cgrp class term
formulari access payer dynam view emgal differenti
asset crowd space updat initi launch
olumi baricitinib think potenti upsid opportun
strategi olumi chang real-world data emerg
neurolog portfolio strategi neurolog pipelin term
priorit plan continu expand segment
tanezumab long-term safeti data expect near term file expect
give us better sens your hope data show
commun whether extern fda intern
threshold need met success approval/commerci uptak
pipelin think priorit strategi late-stag asset
mirikizumab pegilodecakin think potenti role drive
top line growth give us better sens timelin addit data/mileston
asset
celgen acquisit speak rational behind deal
confid posit impact base busi look forward light
recent pushback sharehold wellington starboard dodg cox
think upcom vote next month tell sharehold instil
sens confid deal success close
lung re-fil strategi nsclc sbla re-fil plan
re-fil regardless part data show make
sens wait part read
scenario youd wait re-fil
 see total os data part path forward
tmb doesnt show evid marker os respons
lung trend provid us updat opdivo trend lung/rat
eros keytruda penetr market expect go forward
keytruda soc
rational push back readout
could see data potenti emerg late time-frame
rcc strategi strategi rcc go forward thought
opdivo/yervoy posit rcc light recent data
doesnt compet data next step would
consid combin opdivo yervoy anoth tki/mor toler regimen
 see fit treatment paradigm look forward
opdivo adjuv program long-term outlook adjuv program
eliqui ip give us sens confid strength ip posit
eliqui concern given tent approv china sunshin lake gener
expect launch risk
celgen ozanimod heard term ozanimod updat much
impact invest case anoth rtf think
meaning displac gilenya nv drug go gener
celgen revlimid think two revlimid trial consolid run
two separ trial govern shutdown impact timelin
obvious introduct humira biosimilar ou continu play
sens well idea eros curv look like
lesson learn youll abl appli us regard humira
youv highlight orilissa /elagolix key driver move forward given
endometriosi uterin fibroid new market need happen
commerci perspect reach target sale
critic first-mov advantag orilissa potenti competitor
relugolix much differenti add-back therapi option room
multipl player
data upadacitinib rheumatoid arthriti strong jak inhibitor
class look increasingli crowd give us sens plan address
competit dynam leverag experi across
target non-humira sale growth critic step
need happen achiev revenu goal
setback rova-t impact approach busi develop
overal appetit
beyond bigger asset like upadacitinib risankizumab imbruvica
program your excit
john mchutchison cso head
biktarvi growth one strongest hiv key element
drive growth fraction prescrib think wait see
real-world experi like
give us sens biktarvi ou reimburs discuss
like tdf viiv dolutegravir regimen durabl euwhat
commerci plan biktarvi
prep start ramp dramat us usersalthough
indic approv fda barrier uptak
outlook look like descovi
think landscap hiv like evolv long-act agent
gilead plan address chang develop program hiv
excit
regard yescarta point think commerci infrastructur start
scale still capac constraint driven physic infrastructur
molecul
youv recent ad car-t technolog platform maxcyt cell design
lab sangamocan provid high-level thought long-term plan
field evolv technolog go critic get
given result stellar still optimist prospect selonsertib
still believ combin approach optim develop path
jak inhibitor class like becom crowd gilead compet
space filgotinib follow recent news pfizer xeljanz think
regul go cautiou move forward safeti
outlook jakafi gvhd chang follow fda decis
extend pdufa date agenc provid feedback interim
discuss gone
pre-launch commerci groundwork gvhd done sort
synergi exist gvhd myelofibrosis/ polycythemia vera commerci
infrastructur potenti leverag itacitinib
think market dynam like chang follow potenti
launch celgen fedratinib year end provid insight complet
larg potenti driver atop dermat olumi think recent
news regard pfizer xeljanz like limit use class
commerci standpoint much infrastructur pemigatinib
cholangiocarcinoma leverag bladder cancer
bladder cancer landscap like chang near term jnj erdafitinib
seattl genet ev plan posit pemigatinib market larg enough
support new player
current compound develop asset early-stag
pipelin bullish point pipelin especi earli
stage larg capac constraint given avail resourc
one-on-on meet
tripl combin timelin step remain gener tripl combo nda
packag beyond evalu data select regimen efficaci look similar
combo decis two come
safeti factor could swing decis opportun
find expedit path market least het-min patient possibl
see receiv prioriti review
tripl combin reimburs approach reimburs
negoti tripl combin outsid given superior profil
compar orkambi symkevi tripl could expect command higher price
much addit pushback expect strategi place
respond learn previou negoti benefit
step cystic fibrosi rais bar cf beyond tripl
combo besid newer corrector approach think look promis
strategi patient nonsens mutat statu moderna
collabor expect next updat
geograph expans strategi expand geographi
beyond current activ eu canada australia
area identifi founder effect may creat popul signific
number cf patient
capit alloc signific cash accumul balanc sheet
capit alloc strategi evolv investor expect increas
busi develop activ plan balanc addit intern
spend vs acquir extern asset return capit sharehold
non-cf pipelin cadenc new program enter clinic
could start see data antitrypsin defici focal
segment glomerulosclerosi fsg program factor determin
decis indic go forward pain program whether
find partner develop program
give us updat perform expand ingrezza sale team
see traction talk td awar program diagnos
patient addit market share look achiev year
effort success ad patient therapi date
addit inform learn biomark data outsid
think androgen level acth ultim use
best worst case scenario see play fda
design pivot trial
still track complet nda packag submit opicapon
fda submit addit step need take launch
much invest need go success launch
nda submiss orilissa uterin fibroid still schedul
submit assum approv launch step taken capit
earlier launch competitor
voyag acquisit think busi develop
activ go forward focu early-stag asset focu
progress market late-stag product
still earli launch give us sens adcetri perform
market physician feedback thu far expect see
acceler use market
hodgkin lymphoma differenti avd abvd use
continu drive penetr market percent market share
would like achiev first-lin year
give addit insight thought move forward
regulatori submiss orr would comfort submit fda
data tucatinib due later year see use
drug evolv market earlier line therapi time addit
previous note colorect cancer data tucatinib due
near term expect data posit level confid would
move forward indic gastric cancer
bar orr target relaps cervic cancer tisotumab
vedotin given previous saw respons rate prior studi
indic combin excit potenti achiev respons rate
youv talk potenti patient popul linzess
ironwood need acceler growth volum get current base
discuss strategi
greatest challeng expand patient volum
like evolv near term
patient sub-popul think offer greatest upsid near term
critic potenti abdomin symptom label delay releas formul
last quarter price dynam challeng
expect trend move forward
provid updat enrol gerd studi although
admittedli earli start look potenti commerci strategi
one state goal split near/nearer-term profit cost
associ split decis leav gout market addit
restructur cost outlook chang
lynn seeli presid ceo
upcom readout expect upcom uterin fibroid
endometriosi phase readout result replic phase suffici much
advantag bone miner densiti loss think necessari differenti
endometriosi market develop abbvi orilissa still earli stage
launch view endometriosi market develop far
seen point inform launch strategi
durat therapi expect term durat therapi
endometriosi uterin fibroid anticip label similar low-dos
orilissa month given potenti better safeti profil add-back
think durat like real-world set
opportun ex-u view relugolix opportun ex-u
evalu trade-off potenti larg eu market price concess
could necessari penetr market
prostat cancer phase data prostat cancer expect later year
investor think market opportun feedback gotten
physician patient prefer oral gnrh antagonist
current avail inject
think busi strategi move forward asset develop
look partnership develop pipelin cadenc
convers
walk vet process move potenti asset forward
develop abil develop mani program fairli rapidli seen
posit robust pipelin neg distract
high level differenti lipid nanoparticl deliveri system
give confid optim construct ensur deliveri result
modal platform prophylact vaccin prolif
date remain modal potenti product
given roughli program develop balanc ad addit
program platform keep oper expens check addit
opportun non-dilut fund move program forward top prior
fund barda darpa etc
lead asset give detail see use case
asset asthma market consid market product moderate-to-
novarti compet drug fevipipr set releas phase data
walk implic outcom includ futur trial design
potenti differ two drug
asset describ learn prior phase
gleevec trial level confid abil inhal version mitig
system toxic seen gleevec design trial account
learn
expect underli mechan drug equal
efficaci ulcer coliti crohn diseas ibd indic
look pipelin portfolio see potenti futur
combin therapi use asset
regard discuss fda addit outcom measur
interest includ rimegep label point gate factor
need submiss
detail benefit file nda zydi tablet form
benefit prevent trial would risk strategi
jeopard nda submiss instead go zydi
assum launch competit allergan ubrogep posit
rimegep physician patient ensur rapid adopt addit step
taken ramp launch
four phase trial troriluzol indic excit
believ highest probabl success
upcom phase trial multipl system atrophi detail
give setup trial expect endpoint efficaci
frontotempor dementia ftd proof concept data bar
upcom proof concept data frontotempor dementia threshold
increas progranulin level may result meaning clinic benefit would
statist signific increas progranulin level suffici
ftd develop path opportun acceler develop
path ftd plan use interim analys potenti get market
faster soon could see clinic benefit ftd patient would abl see
efficaci shorter time-frame seen alzheim diseas ad trial
alzheim diseas program consid current develop program ad
envis alzheim landscap develop time would
potenti get market benefit think provid
competit differenti
early-stag program provid updat amyotroph later
sclerosi parkinson diseas program
safeti balanc safeti concern increas immun activ within
brain seen sign excess inflamm far could limit
abil dose
oncolog program oncolog approach differ current immuno-
oncolog approach throughout industri
one-on-on meet wednesday march
todd jame vice-president ir corpor commun
bristol/celgen deal thought bristol/celgen deal
resourc think bristol could bring bear benefit file launch
durat therapi think durat therapi
expect label think durat play real world
launch prepar prepar way
luspatercept launch need happen meantim ensur success launch
luspatercept market uptak expect luspatercept market
uptak expans patient popul lower-risk myelodysplast syndrom non-
medalist believ think penetr popul similar rate
initi indic
combin trial fedratinib rational behind upcom studi
luspatercept combin fedratinib view could increment benefit
combin two
data expect lead product candid near term
intern convers regard next step program assum
data show strong rational advanc develop could potenti see data
esmo
provid updat statu slate program ind file
yet event disclos press releas color on-going
convers regulatori agenc still track initi patient dose
statu current collabor agreement bluebird
bristol-my potenti addit collabor road
priorit strategi collabor
think current competit landscap see
navig next month given grow number compet
compani space
light upcom present speak
expect present your think compani
perspect see play import role advanc lead asset
develop
detail phase mad prasinezumab data publish end
beyond pk/pd data detail outcom especi meaning
given number anti-alpha-synuclein antibodi develop
includ area potenti differenti prasinezumab your
especi posit
lesson setback al amyloidosi appli
leverag develop attr amyloidosi
preclin amyloid beta program expect move forward
pre-clin data expect end year on-going controversi
amyloid beta hypothesi impact plan develop potenti read-
through competitor antibodi program data present
asset early-stag pipelin primarili excit a-beta tau
recent announc addit bavencio tripl combin
pancreat cancer nektar addit color
provid bavencio would optim checkpoint inhibitor indic
give updat expect top-lin data
readout bioavail studi provid anticip path forward
launch registr studi
iv data schizophrenia alzheim diseas delirium opioid withdraw
shown impress respons rate rang respons rate
target indic
neuroendocrin prostat cancer provid addit color
expect preliminari data histor low
respons rate single-ag checkpoint inhibitor set give detail
level comfort combin therapi keytruda
select new candid move forward emerg program
neurosci immuno-oncolog expect early-stag pipelin
addit next month
bla file import mileston compani year
prepar progress sinc call last month disclos
potenti quarter file
recent note cash posit suffici aspect
bla submiss could requir addit fund order fulfil request
regul
convers physician last month regard
viaskin peanut approv pathway approv see market dynam
competitor play
addit bla viaskin peanut updat investor expect
pipelin regard viaskin milk viaskin egg
bla file plan place prepar launch
addit resourc need ensur success
decis recent made move forward monotherapi
pnh think opportun combin approach recept
payer prescrib
given pnh result concern regard potenti
aspect studi think could leverag ach-
pnh trial lesson learn
alexion next-gener ultomiri recent approv pnh offer less
frequent dose chang market landscap especi someth like
oral inhibitor make recruit patient less difficult
alexion also investig al multipl sclerosi ppm consid
either indic diseas beyond pnh believ
admittedli earli current thought commerci potenti
oral factor inhibitor alon vs partnership given condit rel rare
factor decis
geoff meacham ph herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
